临床与病理杂志
臨床與病理雜誌
림상여병리잡지
International Journal of Pathology and Clinical Medicine
2015年
6期
1189-1194
,共6页
高蓓蓓(综述)%李代强(审校)
高蓓蓓(綜述)%李代彊(審校)
고배배(종술)%리대강(심교)
PD-1/PD-L1%非小细胞肺癌%共刺激分子
PD-1/PD-L1%非小細胞肺癌%共刺激分子
PD-1/PD-L1%비소세포폐암%공자격분자
PD-1/PD-L1%non-small lung cancer (NSCLC)%co-stimulatory molecule
PD-1(programmed cell death-1，程序性死亡受体1)与其配体PD-L1(programmed cell death-ligand 1，程序性死亡配体1)属于CD28/B7家族，是一对共刺激分子，具有负性调控作用。PD-1通过与其配体PD-L1结合调节肿瘤的微环境，使肿瘤细胞免于机体免疫系统的监视和清除。目前已有较多研究显示PD-1/PD-L1在非小细胞肺癌组织中的表达水平与患者的临床病理因素及预后存在显著的相关性。在非小细胞肺癌的治疗领域，以PD-1/PD-L1为代表的免疫治疗成为继手术治疗、化疗、放疗、分子靶向治疗之后的新焦点。PD-1/PD-L1抑制剂在一系列非小细胞肺癌临床试验中也显示出了巨大的临床潜力。本文就PD-1/PD-L1的生物学结构及其在非小细胞肺癌中的作用机制、研究进展及展望作一综述。
PD-1(programmed cell death-1，程序性死亡受體1)與其配體PD-L1(programmed cell death-ligand 1，程序性死亡配體1)屬于CD28/B7傢族，是一對共刺激分子，具有負性調控作用。PD-1通過與其配體PD-L1結閤調節腫瘤的微環境，使腫瘤細胞免于機體免疫繫統的鑑視和清除。目前已有較多研究顯示PD-1/PD-L1在非小細胞肺癌組織中的錶達水平與患者的臨床病理因素及預後存在顯著的相關性。在非小細胞肺癌的治療領域，以PD-1/PD-L1為代錶的免疫治療成為繼手術治療、化療、放療、分子靶嚮治療之後的新焦點。PD-1/PD-L1抑製劑在一繫列非小細胞肺癌臨床試驗中也顯示齣瞭巨大的臨床潛力。本文就PD-1/PD-L1的生物學結構及其在非小細胞肺癌中的作用機製、研究進展及展望作一綜述。
PD-1(programmed cell death-1，정서성사망수체1)여기배체PD-L1(programmed cell death-ligand 1，정서성사망배체1)속우CD28/B7가족，시일대공자격분자，구유부성조공작용。PD-1통과여기배체PD-L1결합조절종류적미배경，사종류세포면우궤체면역계통적감시화청제。목전이유교다연구현시PD-1/PD-L1재비소세포폐암조직중적표체수평여환자적림상병리인소급예후존재현저적상관성。재비소세포폐암적치료영역，이PD-1/PD-L1위대표적면역치료성위계수술치료、화료、방료、분자파향치료지후적신초점。PD-1/PD-L1억제제재일계렬비소세포폐암림상시험중야현시출료거대적림상잠력。본문취PD-1/PD-L1적생물학결구급기재비소세포폐암중적작용궤제、연구진전급전망작일종술。
PD-1 (programmed cell death, PD-1) and its ligand PD-L1 (programmed cell death-ligand 1, PD-L1) belonged to the immunoglobulin superfamily of CD28/B7, is a pair of co-stimulatory molecule which has negative regulation effect. Combined with ligands, PD-1 could modulate the tumor microenvironment, leading the tumor cells scape from host Immune surveillance and elimination. Recently, many studies showed that PD-1/PD-L1 expression in non-small cell lung cancer (NSCLC) was substantially related to clinicopathologic and prognostic factors of patients. Atfer surgery, chemotherapy, radiotherapy and molecular targeting therapy, immune therapy targeting PD-1/PD-L1 has become the new focus of NSCLC therapy in recent years. It has shown durable responses in clinical trials with large NSCLC expansion cohorts. This review summarizes the biological structure and the critical role of PD 1/PD-L1 in NSCLC as well as its current research status and future direction.
